News Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer Staff September 11, 2023 Iframe sync Post navigation Previous: Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T RelapseNext: EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023 More Stories Fitness News UREVO Announces Black Friday Sale 2026 with Its Biggest Discounts of the Year Staff November 18, 2026 News Pharmaceutical Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Increased Dose of 15 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study Staff November 18, 2026 Cancer Clinical Trial Diagnostics DNA Medicare News Patient Care Pharmaceutical Adaptive Biotechnologies Highlights clonoSEQ’s Central Role in Advancing MRD-Guided Care Across Hematology at ASH 2026 Staff November 18, 2026